Blood pressure was improved
in
85% with Gerovital; control group, 63.8%.
Heart problems were improved in 85.2%
with Gerovitalcontrol group, 63.8%
High pulse rate was normalized in 93%
of the Gerovital group, control group, 88%.
Low pulse rate was normalized in 9%
more
of the GH3 treated patients.
Respiratory capacity was unchanged in
96.1% of the Gerovital patients as opposed to 91.2% in the
control
group.
This is significant because lung capacity decreases rapidly
during the
late, middle years. Stabilizing lung capacity in patients of
these ages
implies a retardation of the aging process.
Cardiovascular effect of those
showing
a low heart rate. Gerovital maintained most patients at the same
level
for two years when a slow decline would be normally expected.
Muscular strength there were
significant
improvements in twice as many of the Gerovital patients than the
control
group. 25.9% showed improvement with Gerovital when a decline of
muscle
power is expected.
Work absences diminished 40% with the GH3
patients.
Also 77% of the GH3 group performed their work production norms,
whereas
20% actually exceeded their usual work performance.
Protocol
GeroVital® H3 Tablets
Protocol GeroVital H3 Vials/
Inject.
To
Order
Gerovital Tablets and Injections: